Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Ovarian Neoplasms

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 27 articles:
HTML format



Single Articles


    May 2025
  1. SHAH M, Chen TY, Ison G, Fiero MH, et al
    Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
    J Clin Oncol. 2025 May 19:JCO2402834. doi: 10.1200/JCO-24-02834.
    PubMed     Abstract available


    January 2025
  2. GAILLARD S, Lacchetti C, Armstrong DK, Cliby WA, et al
    Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.
    J Clin Oncol. 2025 Jan 22:JCO2402589. doi: 10.1200/JCO-24-02589.
    PubMed     Abstract available


    December 2024
  3. SCAMBIA G, Villalobos Valencia R, Colombo N, Cibula D, et al
    Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.
    J Clin Oncol. 2024 Dec 12:JCO2400933. doi: 10.1200/JCO.24.00933.
    PubMed     Abstract available


    November 2024
  4. FAGOTTI A, Costantini B, Fanfani F, Giannarelli D, et al
    Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18).
    J Clin Oncol. 2024 Nov 21:JCO2400686. doi: 10.1200/JCO.24.00686.
    PubMed     Abstract available


    October 2024
  5. CHLEBOWSKI RT, Aragaki AK, Pan K, Haque R, et al
    Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials.
    J Clin Oncol. 2024;42:3537-3549.
    PubMed     Abstract available


  6. BERGSTROM EN, Abbasi A, Diaz-Gay M, Galland L, et al
    Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides.
    J Clin Oncol. 2024;42:3550-3560.
    PubMed     Abstract available


  7. LEE JM, Brady MF, Miller A, Moore RG, et al
    Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
    J Clin Oncol. 2024 Oct 3:JCO2400683. doi: 10.1200/JCO.24.00683.
    PubMed     Abstract available


    September 2024
  8. GONZALEZ-MARTIN A, Rubio MJ, Heitz F, Depont Christensen R, et al
    Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
    J Clin Oncol. 2024 Sep 18:JCO2400668. doi: 10.1200/JCO.24.00668.
    PubMed     Abstract available


    August 2024
  9. O'BRIEN KM, Wentzensen N, Ogunsina K, Weinberg CR, et al
    Intimate Care Products and Incidence of Hormone-Related Cancers: A Quantitative Bias Analysis.
    J Clin Oncol. 2024;42:2645-2659.
    PubMed     Abstract available


    May 2024
  10. LANDEN CN, Buckanovich RJ, Sill MW, Mannel RS, et al
    Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
    J Clin Oncol. 2024 May 22:JCO2302076. doi: 10.1200/JCO.23.02076.
    PubMed     Abstract available


  11. HARRIS HR, Davis CP, Terry KL
    Epidemiologic Methods to Advance Our Understanding of Ovarian Cancer Risk.
    J Clin Oncol. 2024 May 15:JCO2400602. doi: 10.1200/JCO.24.00602.
    PubMed    


    April 2024
  12. MUTLU SUTCUOGLU B, Sutcuoglu O
    Interpretation of the EORTC-55954 Trial: Does the Response to Neoadjuvant Chemotherapy Have an Effect on Disease Outcome?
    J Clin Oncol. 2024;42:1204-1205.
    PubMed    


  13. HAN CY, Lu KH, Corrigan G, Perez A, et al
    Normal Risk Ovarian Screening Study: 21-Year Update.
    J Clin Oncol. 2024;42:1102-1109.
    PubMed     Abstract available


    February 2024
  14. LORUSSO D, Raspagliesi F, Ronzulli D, Valabrega G, et al
    Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
    J Clin Oncol. 2024 Feb 5:JCO2301225. doi: 10.1200/JCO.23.01225.
    PubMed     Abstract available


  15. PAVLIK EJ, van Nagell JR Jr, Dietrich CS 3rd, Ueland FR, et al
    Compelling Story of Ovarian Cancer Screening.
    J Clin Oncol. 2024 Feb 2:JCO2302424. doi: 10.1200/JCO.23.02424.
    PubMed    


    January 2024
  16. TJOKROWIDJAJA A, Friedlander ML, Ledermann JA, Coleman RL, et al
    Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
    J Clin Oncol. 2024 Jan 12:JCO2301182. doi: 10.1200/JCO.23.01182.
    PubMed     Abstract available


    November 2023
  17. LAVERY JA, Boutros PC, Scott JM, Tammela T, et al
    Pan-Cancer Analysis of Postdiagnosis Exercise and Mortality.
    J Clin Oncol. 2023;41:4982-4992.
    PubMed     Abstract available


  18. ST LAURENT J, Liu JF
    Treatment Approaches for Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2023 Nov 1:JCO2301771. doi: 10.1200/JCO.23.01771.
    PubMed     Abstract available


    October 2023
  19. AREND RC, Monk BJ, Shapira-Frommer R, Haggerty AF, et al
    Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
    J Clin Oncol. 2023 Oct 31:JCO2202915. doi: 10.1200/JCO.22.02915.
    PubMed     Abstract available


    September 2023
  20. OZOLS RF, Bundy BN, Greer BE, Fowler JM, et al
    Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study.
    J Clin Oncol. 2023;41:4077-4083.
    PubMed     Abstract available


  21. SPRIGGS DR, Fleming GF
    Flashback Foreword: Cytoreductive Surgery for Ovarian Carcinoma and Carboplatin + Paclitaxel in Ovarian Cancer.
    J Clin Oncol. 2023;41:4063-4064.
    PubMed    


    August 2023
  22. KURTZ JE, Pujade-Lauraine E, Oaknin A, Belin L, et al
    Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
    J Clin Oncol. 2023 Aug 29:JCO2300529. doi: 10.1200/JCO.23.00529.
    PubMed     Abstract available


  23. MCCAW ZR, Tian L, Wei LJ
    Evaluating the Duration of Response With Mirvetuximab Soravtansine for Treating Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2023 Aug 3:JCO2300288. doi: 10.1200/JCO.23.00288.
    PubMed    


    June 2023
  24. COLOMBO N, Van Gorp T, Matulonis UA, Oaknin A, et al
    Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
    J Clin Oncol. 2023 Jun 26:JCO2202624. doi: 10.1200/JCO.22.02624.
    PubMed     Abstract available


    May 2023
  25. KINNEY AY, Walters ST, Lin Y, Lu SE, et al
    Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
    J Clin Oncol. 2023;41:2767-2778.
    PubMed     Abstract available


  26. STROOT IAS, Brouwer J, Bart J, Hollema H, et al
    High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors.
    J Clin Oncol. 2023;41:2523-2535.
    PubMed     Abstract available


    March 2023
  27. FU S, Yao S, Yuan Y, Previs RA, et al
    Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.
    J Clin Oncol. 2023;41:1725-1734.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.